Reboxetine

a drug of the norepinephrine reuptake inhibitor (NRI) class, marketed as an antidepressant by Pfizer for use in the treatment of major depression, although it has also been used off-label for panic disorder and attention deficit hyperactivity disorder (ADHD).

Reboxetine

Vestra, (S,S)-reboxetine, Esreboxetine; Reboxetine

Narebox, Reboot, Rebotin, Reboxxin

(2R)-2-[(R)-(2-ethoxyphenoxy)(phenyl)methyl]morpholine

98% protein binding.

It is a selective NaRI (noradrenaline reuptake inhibitor), and an ariloxybenzyl derivative of morpholine. Prescribe to treat depression and also has been found useful in the treatment of panic disorders and narcolepsy.

4 mg bid, may increase to 10 mg daily after 3-4 weeks if necessary. Max: 12 mg daily.

For the treatment of clinical depression.

Dysuria, impotence, postural hypotension, insomnia, dizziness, increased sweating, dry mouth, constipation, dry mouth, urinary hesitancy, paraesthesia, hyponatraemia, tachycardia.

• Avoid concomitant admin with antipsychotics, antiarrhythmics, ciclosporin, imidazole and triazole antifungals, TCAs.
• Concurrent use with CYP3A4 inhibitors may increase plasma levels of reboxetine.
• Risk of hypertensive crisis when used with MAOIs.
• Concurrent use with ergot derivatives may increase BP.

Contraindicated in pregnancy and lactation.

Store it at room temperature.

Molecular weight

313.397

Molecular formula

C19H23NO3

CAS number

71620-89-8

Precautions

• Benign prostatic hyperplasia, Renal and hepatic impairment, epilepsy, cardiac disorders, bipolar disorders, glaucoma, urinary retention.
• May impair ability to perform tasks requiring mental alertness, driving or operating machinery.
• Monitor for signs of clinical worsening.